

Name and surname: ROSA LAMARCA CASADO
Cell phone number: +34 676952854
email: lamarccasado.rosa@gmail.com

PROFILE

More than 20 years of experience in the pharmaceutical industry. Leading and managing teams of statisticians and statistical programmers since 2004. These teams made significant achievements in making new drugs available to patients by means of successful global clinical developments, regulatory submission packages and pricing and reimbursement dossiers. Experienced in providing strategies to handle the statistical support required by several departments. Facilitate and promote the personal development of team members, encourage the implementation of novel statistical methods and programming approaches. Previously, I spent 8 years in the epidemiology field getting experience in longitudinal studies and development and use of health-related quality of life instruments.

Extensive experience with interactions with FDA and EMA as well as national regulatory bodies, being a member of the Acildinium team in the FDA advisory Committee. Expertise in partnership, pricing & reimbursement activities, epidemiology and patient reported outcomes.

Involvement with the scientific community being part of the board of the Catalan Statistical Society, attendance to conferences and publications in journals. The two most important publications are N Engl J Med. 2018;378:1865-76 and N Engl J Med. 2018;378:1877-1887 that were the basis for the most relevant change in the GINA guidelines (asthma guidelines) in the last 30 years.

PROFESSIONAL EXPERIENCE

Positions:

Senior Statistical Science Director at AstraZeneca- Biometrics Team Leader, 2019- present

Statistical Director at AstraZeneca- Biometrics Team Leader, July 2017 - 2019

Associate Statistical Director at AstraZeneca, January 2016 – June 2017

Head of Clinical Statistics (statistics and programming) at Ammirall, 2011- 2016

Head of Biometry (data management, statistics and programming) at Ammirall, 2009-2011

Head of Biometry Operations (data management, statistics and programming) at Ammirall, 2004-2008

Project statistician at Ammirall, 2001-2003

Researcher in the Health Services Research Unit at IMIM:1999-2001

Research fellow (grant from Carlos III Research Institute) in the Health Services Research Unit at IMIM :1995-1999

Research fellow (grant from Researcher in epidemiology at the medical research center Institut Municipal de Investigació Mèdica (IMIM):1994-1995

Main therapeutic areas: Respiratory, Dermatology, Pain and Elderly

Expertise on: Clinical development, Regulatory submissions, Health related quality of life instruments, Pricing and Reimbursement and Epidemiology.

EDUCATION

PhD in Health and Life Sciences by the Pompeu Fabra University, 2004-2006

MSc in Science and Statistical Techniques by the Universitat Politècnica de Catalunya, 1999-2001

MSc in Applied Statistics by the Sheffield Hallam University, 1995-1997

Course on Pedagogical Ability (Secondary School Teaching) by the Universitat Politècnica de Catalunya, 1994-1995

BSc in Statistics by the Universitat Politècnica de Catalunya, 1991-1994

STAYS ABROAD

Guest researcher in the Biostatistics department and Research on Health Services department Copenhagen University, Denmark, (4 months) 1999

TEACHING EXPERIENCE

Teacher in the Master of Public Health (Biostatistics I). Pompeu Fabra University, 2000-2006

Teacher in the MIR (Resident Interns) programme of Occupational Medicine. Pompeu Fabra University, 2004-2005

Teacher in the Master of Public Health (Biostatistics II). Pompeu Fabra University, 2000-2001

Teaching Assistant in the MBA programme. ESADE Business School, 1998-2001

PROFESSIONAL MEMBERSHIPS

Member of the 'Societat Catalana d'Estadística' (SoCE) from 2010.

Almirall representative in 'European Heads of Clinical Data Management' (2010-2011).

Caucus for women in statistics 2021-2022

Member of Statisticians in the Pharmaceutical Industry (PSI) (2015-2016, 2021-2022)

Member of the American Statistical Association (1995-1997)

Member of the Spanish Association in Statistics and Operation Research (1996-1998).

PARTICIPATION IN SCIENTIFIC SOCIETIES

President of the Catalan Society of Statistics (SoCE) from Dec 2016- 2019.

Member of the Board of the SoCE from 2012-2019.

Spanish representative in the European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) (2003-2004)

PARTICIPATION IN THE ORGANISATION OF SCIENTIFIC CONFERENCES

Member of the Scientific Committee of the Pharmaceutical Statistics in the Industry (PSI). PSI Annual Conference 2020.

Member of the Scientific Committee of the 38th Annual Conference of the International Society for Clinical Biostatistics (ISCB) 2017.

Co- organizer (R. Lamarca and F Bretz) of the mini-symposia on "Choosing Estimands in a Clinical trial" in the 38th ISCB 2017.

Member of the Advisory Council of Big Data Center of Excellence (CoE) Barcelona. Eurecat- BDigital. 2015- 2018.

PATENTS CO-AUTHORSHIP

Authorship of three European patents: EP2100598A1, EP2100599A1, and EP2666465 presented in 2009, 2009 and 2013, respectively. Patents are property of Almirall SA.

REGULATORY SUBMISSION APPROVALS

Leading the biometry teams that got the following regulatory submission approvals:

- Budesonide and formoterol combination (Symbicort®):
 - sNDA Symbicort pMDI for the use of Symbicort for pediatric asthma patients (approved in 2017)
 - sNDA LABA safety approved, removing the Boxed Warning concerning asthma related deaths
 - Asthma pMDI in Russia approved
 - sNDA extending its use to include the reduction of COPD exacerbations (approved in 2017)
 - Bridging TBH to pMDI: EU approval in 2020
 - Anti-inflammatory reliever in mild asthma, first approval in 2019:
 - More than 30 countries approval
 - Generating evidence that supports the most relevant update in the international asthma guidelines
- Acclidinium bromide and formoterol combination (Duaklir® Pressair® in the US / Duaklir® Genuair® in the EU):
 - NDA (approved in 2019), MAA (approved in 2014) and rest of the world (RoW) approvals
 - Positive added value in payers assessment
- Acclidinium bromide(Tudorza® Pressair® in the US /Eklira® Genuair® in the EU)
 - Member of the Acclidinium team in the FDA advisory Committee (PADAC) in 2011
 - NDA, MAA (both approved in 2012) and rest of the world (RoW) approvals
 - Positive added value in payers assessment
 - sNDA approval (including information regarding major adverse cardiovascular events (MACE) and reduction in COPD exacerbations) (approved in 2019)
 - Positive Type II variation in EU to include information regarding major adverse cardiovascular events (MACE) and reduction in COPD exacerbations (approved in 2019)
- Pulmicort®:
 - Label extension for croup, COPD exacerbations and asthma exacerbation across different countries in 2020-2021
- Linaclotide: approved in 2012 (Constella® in the EU) for the treatment of Irritable Bowel Syndrome- Constipation (IBS-C)
- Dimethyl Fumarate: approved in 2017 (Skilarence®) in the EU as a first-line induction and long-term treatment for adults with moderate-to-severe chronic plaque psoriasis.

PhD EXAMINING BOARD

Member of the tribunal appointed for the evaluation of the thesis "Statistical methods and software for clinical trials with binary and survival endpoints. Efficiency, sample size and two-sample comparison" defended by Marta Bofill Roig, director Prof Lupe Gómez, at the Universitat Politècnica de Catalunya. Barcelona, 22nd December 2020. Tribunal members (Nuria Porta - the Institute of Cancer Research (Secretary), Jordi Ocaña Rebull – University of Barcelona (President), Rosa Lamarca - AstraZeneca (Vocal), Thomas Jaki - University of Cambridge (Vocal), Martin Posch – Medical University of Vienna (Vocal).

ORAL PRESENTATIONS, CONFERENCES AND ONE-DAY COURSES

IQS. Postgraduate program in Biotech and Pharmaceutical Industry. Statistics section. Barcelona, 2 February 2018

38th Annual Conference of the International Society for Clinical Biostatistics: "Choosing Estimands in a Clinical trial: Introduction". Vigo 9-13 July 2017.

49th SEPAR congress. "Síntomas matutinos y nocturnos en EPOC y eficacia de aclidinio/formoterol en pacientes sintomáticos vs. asintomáticos". Granada 10-13 June 2016.

7th Encuentro de Bioestadísticos. Universidad Complutense de Madrid. Ensayos clínicos: multiplicidad, variables compuestas, y datos faltantes (Clinical trials: multiplicity, composite endpoints, and missing data). Madrid, 17th June 2015.

IL3- Barcelona University. Pharmaceutical Industry programme (organiser and teacher). "¿Cómo evaluar nuevos medicamentos, diferentes formulaciones y genéricos: estudios de superioridad, no-inferioridad y equivalencia y su metodología estadística?" (How to assess new medicines, formulations, and generics: superiority, non-inferiority and equivalence and its statistical methodology). Barcelona, 7th May 2015.

8th Annual Optimizing Clinical Trials Summit: Site Selection, Feasibility & Patient Recruitment. "Do twin trials really exist?". Barcelona, 12-13 November 2014.

Joint DIA/AEMPS Statistics Workshop. Statistical Methodology in Clinical R&D. Panelist in "Lack of adherence and the choice of the right estimand in clinical trials" Barcelona, 10-11 November 2014.

6th Annual Conference on COPD. "Morning and night-time symptoms in COPD". London, 20-21st October 2014.

Real Life studies Workshop. Almirall SA. "Observational studies". Barcelona, 15th July 2014.

Catalan Parliament. Celebration of the International Year of Statistics. "Statisticians in the Industry". Barcelona, 18th October 2013.

5th Annual Conference on COPD. "Assessing exacerbations in COPD clinical trials". London, 17th October 2013.

Trials and Truths Workshop. Universitat Politècnica de Catalunya (UPC). "Time to change: disclosing clinical trials". Barcelona, 8th March 2013.

I Workshop on Statistical Consulting and Software, Universitat Autònoma de Barcelona 'The statistician role in drug development. Barcelona, 26-28 September.

Survival Analysis Course. Fundació les Heures, Barcelona University, Barcelona, 2002.

Conference 'Survival analysis approaches to the AIDS studies', CEESCAT (Center for Epidemiological Studies on HIV/AIDS of Catalonia) Badalona, 8th February 2001.

Clase: "Elaboración y calibración de instrumentos de medida" en el curso 'Métodos, técnicas y instrumentos para la investigación biomédica' incluido en el programa de doctorado de Ciencias de la Vida de la Universidad Pompeu Fabra, Barcelona, 10/abril/2000.

Course 'Assessing Quality of Life'. Master in Evaluación y Gestión de Servicios Sanitarios. Organizado por Health Technology Assessment of Catalonia, 3 -5th February 2000.

'Longitudinal analysis'. PhD programme. Department of Experimental and Health Sciences. Universitat Autònoma de Barcelona, Barcelona, 27th January 2000.

Conference 'Survival analysis in the elderly population'. Johns Hopkins University, Baltimore, 23rd November 1999.

Workshop 'Cross-cultural adaptation of health related quality of life questionnaires'. Barcelona, 3rd November 1999.

Conference 'Counting processes for the analysis of time-dependent variables in the survival analysis setting'. Valencia, 16th July 1999.

Conference 'Weighted truncation in the Cox regression'. Association of Clinical Biometry in Pharmaceutical Research. Barcelona, 17th April, 1996.

PUBLICATIONS

Bateman ED, O'Byrne PM, FitzGerald JM, Barnes PJ, Zheng J, Lamarca R, Puu M, Parikh H, Alagappan V, Reddel HK. Positioning As-needed Budesonide-Formoterol for Mild Asthma: Effect of Pre-study Treatment in Pooled Analysis of SYGMA 1 and 2. *Ann Am Thorac Soc* 2021.

Link to article: <https://www.atsjournals.org/doi/10.1513/AnnalsATS.202011-1386OC>

Reddel HK, O'Byrne PM, FitzGerald JM, Barnes PJ, Zheng J, Ivanov S, Lamarca R, Puu M, Alagappan VKT, Bateman ED. Efficacy and Safety of As-Needed Budesonide-Formoterol in Adolescents with Mild Asthma. *J Allergy Clin Immunol Pract*. 2021 Apr 22;S2213-2198(21)00456-6.

Link to article: DOI: 10.1016/j.jaip.2021.04.016

FitzGerald JM, O'Byrne PM, Bateman ED, Barnes PJ, Zheng J, Ivanov S, Lamarca R, Larsdotter U, Emerath U, Jansen G, Puu M, Alagappan VKT, Surmont F, and Reddel HK. Safety of as-needed budesonide-formoterol in mild asthma: data from the two phase III SYGMA studies. *Drug Safety* 2021.

Link to article: <https://doi.org/10.1007/s40264-020-01041-z>

Ferguson GT, Skärby T, Nordenmark LH, Lamarca R, Aksomaitye A, Lythgoe D, Gilbert I, Trudo F. Unreported and overlooked: a post hoc analysis of COPD symptom-related attacks from the RISE study. *Int J COPD* 2020;15:3123-3134.

O'Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zheng J, Gustafson P, Lamarca R, Puu M, Keen C, Alagappan VKT, Reddel HK. Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study. *Lancet Respir Med* 2020. Published Online October 1, 2020

Link to article: [https://doi.org/10.1016/S2213-2600\(20\)30416-1](https://doi.org/10.1016/S2213-2600(20)30416-1)

Link to accompanying editorial: [https://doi.org/10.1016/S2213-2600\(20\)30465-3](https://doi.org/10.1016/S2213-2600(20)30465-3)

Featured article of the week.

O'Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Ivanov S, Reddel HK. Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. *N Engl J Med*. 2018 May 17;378(20):1865-1876. doi: 10.1056/NEJMoa1715274.

Link to article: <https://www.nejm.org/doi/pdf/10.1056/NEJMoa1715274>

Link to accompanying editorial: <https://www.nejm.org/doi/pdf/10.1056/NEJMe1802680>

Bateman ED, Reddel HK, O'Byrne PM, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Siwek-Posluszna A, FitzGerald JM. As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma. *N Engl J Med*. 2018 May 17;378(20):1877-1887. doi: 10.1056/NEJMoa1715275.

Link to article: <https://www.nejm.org/doi/pdf/10.1056/NEJMoa1715275>

Link to accompanying editorial: <https://www.nejm.org/doi/pdf/10.1056/NEJMe1802680>

Gillen M, Forte Salto P, Lamarca R, Burke J, Svensson J-O, Rask K, Larsdotter U, Eckerwall G. Effect of a spacer on total systemic and lung bioavailability in healthy volunteers and in vitro performance of the Symbicort® (budesonide/formoterol) pressurized metered dose inhaler. *Pulmon Pharmacol Ther* 2018;52:7-17 (DOI: 10.1016/j.pupt.2018.08.001)

Link to article: <https://www.sciencedirect.com/science/article/pii/S1094553917303000?via%3Dihub>

Pearlman DS, Eckerwall G, McLaren J, Lamarca R, Puu M, Gilbert I, Jorup C, Sandin K, Lanz MJ. Efficacy and safety of budesonide/formoterol pMDI vs budesonide pMDI in asthmatic children (6-<12 years). *Ann Allergy Asthma Immunol*. 2017 Apr;118(4):489-499.e1. doi: 10.1016/j.anai.2017.01.020.

Mrowietz U, Szepletowski JC, Loewe R, van de Kerkhof P, Lamarca R, Ocker WG, Tebbs VM, Pau-Charles I. Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm® - and placebo-controlled trial (BRIDGE). *Br J Dermatol*. 2017 Mar;176(3):615-623. doi: 10.1111/bjd.14947.

Jones PW, Leidy NK, Hareendran A, Lamarca R, Chuecos F, Garcia Gil E. The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies. *Respir Res*. 2016 May 23;17(1):61. doi: 10.1186/s12931-016-0372-1.

Wedzicha JA, Agusti A, Donaldson G, Chuecos F, Lamarca R, Garcia Gil E. Effect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: A pooled analysis of five Phase III, randomized, placebo-controlled studies. *COPD: Journal of Chronic Obstructive Pulmonary Disease* 2016, DOI:10.3109/15412555.2016.1170111.

Lamarca R and Herrera D. Editorial. Beyond data sharing. *Med Clin (Bcn)* 2015. Apr 2. pii: S0025-7753(15)00106-2. doi: 10.1016/j.medcli.2015.02.005. [Epub ahead of print].

Jones PW, Lamarca R, Chuecos F, Singh D, Agustí A, Bateman ED, de Miquel G, Caracta C, Garcia Gil E. Characterisation and impact of reported and unreported exacerbations: results from ATTAIN. *Eur Respir J*. 2014 Sep 18. pii: erj00388-2014. [Epub ahead of print]

Jones PW, Singh D, Bateman ED, Agustí A, Lamarca R, de Miquel G, Segarra R, Caracta C, Garcia Gil E. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: The ATTAIN study. *Eur Respir J*. 2012;40(4):830-836.

Jones PW, Rennard SI, Agustí A, Chanez P, Magnussen H, Fabbri L, Donohue JF, Bateman ED, Gross NJ, Lamarca R, Caracta C, Garcia Gil E. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. *Respir Res*. 2011;12:55.

Joos GF, Schellhout VJ, Pauwels RA, Kanniss F, Magnussen H, Lamarca R, Jansat JM, Garcia Gil E. Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients. *Respir Med*. 2010;104(6):865-872.

Chanez P, Burge PS, Dahl R, Creemers J, Chuchalin A, Lamarca R, Garcia Gil E. Aclidinium bromide provides long-acting bronchodilation in patients with COPD. *Pulm Pharmacol Ther*. 2010;123(1):15-21.

- Jansat JM, Lamarca R, Garcia Gil E, Ferrer P. Safety and pharmacokinetics of single doses of acclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. *Int J Clin Pharmacol Ther.* 2009;47(7):460-468.
- Newman SP, Sutton DJ, Segarra R, Lamarca R, de Miquel G. Lung deposition of acclidinium bromide from Genuair®, a multidose dry powder inhaler. *Respiration.* 2009;78(3):322-328.
- Jansat JM, Lamarca R, de Miquel G, Schrödter A, Miletzki B, Gurniak M. Safety and pharmacokinetics of multiple doses of acclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants. *J Clin Pharmacol.* 2009;49(10):1239-1246.
- Orfila F, Ferrer M, Lamarca R, Tebe C, Domingo-Salvany A and Alonso J. Gender Differences in Health Related Quality of Life among the Elderly: the Role of Objective Functional Capacity and Chronic Conditions. *Soc Sci Med.* 2006;63(9):2367-80.
- Letzel H, Mégard Y, Lamarca R, Raber A and Fortea J. The efficacy and safety of aceclofenac versus placebo and naproxen in women with primary dysmenorrhoea. *Eur J of Obstet Gynecol Reprod Biol.* 2006;129(2):162-8.
- Lamarca R, Ferrer M, Andersen PK, Liestol K, Keiding N, Alonso J. A changing relationship between disability and survival among the elderly at different ages. *J Clin Epidemiol* 2003; 56: 1192-1201.
- Prieto L, Alonso J, Lamarca R. Classical test theory versus Rasch quality of life questionnaire reduction. *Health and Quality of Life Outcomes* 2003; 1(1):27-40.
- Domingo-Salvany A, Lamarca R, Ferrer M, Garcia-Aymerich J, Alonso J, Félez M, Khalaf A, Marrades R, Monsó E, Serra J and Antó JM (for the COPD study group). Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2002;166(5):680-685.
- Miravittles M, Alvarez-Sala JL, Lamarca R, Ferrer M, Masa F, Vereá H, Zalacain R, Murio C, Ros F, Vidal R. Treatment and quality of life in patients with chronic obstructive pulmonary disease. *Qual Life Res* 2002;11(4):329-338.
- Alonso J, Ferrer M, Lamarca R. Dificultades y perspectivas en la medición de la Calidad de Vida Relacionada con la Salud (CVRS). *FMC-Formación Continuada en Atención Primaria* 2001; 8 (supl 2): 29-35.
- Lamarca R, Alonso J, Santed R, Prieto L. Performance of a perceived health measure in different groups of the population: a comprehensive study in Spain. *J Clin Epidemiol* 2001;54(2):127-135.
- Orfila F, Ferrer M, Lamarca R, Alonso J. Evolution of self-rated health status in the elderly: cross-sectional vs. longitudinal estimates. *J Clin Epidemiol* 2000; 53:563-570.
- Alonso J, Lamarca R, Martí J. The pain and function of the hip (PFH) scale: a patient-based instrument for measuring the effectiveness of hip replacement. *Orthopedics* 2000;23(12):1273-7.
- Martí-Valls J, Alonso J, Lamarca R, Pinto JL, Auleda J, Girvent R, López E, Miralles R, Ramon R, Saló JM. Efectividad y costes de la intervención de prótesis total de cadera en siete hospitales de Cataluña. *Med Clin (Bcn)* 2000;114(Supl 2):34-39.
- Sabartés O, Miralles R, Ferrer M, Esperanza A, García-Palleiro P, Llorach I, Guillén J, Lamarca R, Cervera AM. Factores predictivos de retorno al domicilio en pacientes ancianos hospitalizados. [Factors predicting return home of hospitalized aged patients]. *An Med Interna (Madrid)* 1999; 16:407-14.
- Ferrer M, Lamarca R, Orfila F, Alonso J. A comparison between objective and self-rated functional capacity in Spanish elderly. *Am J Epidemiol* 1999; 149(3):228-35.
- Prieto L, Lamarca R, Casado A. La evaluación de la fiabilidad en las observaciones clínicas: el coeficiente de correlación intraclase. *Med Clin (Barc)* 1998; 110:142-145.
- Lamarca R, Gómez G, Muñoz A, Alonso J. Left-truncated data with age as the time-scale: an alternative for survival analysis in the elderly population. *J Gerontol Med Sci* 1998; 53A(4):M337-M343.
- Sunyer J, Lamarca R, Alonso J. Smoking after 65 years of age and mortality in Barcelona-city. *Am J Epidemiol* 1998; 148(6):575-80. (discussion paper in Institut Català de la Salut. *Recull de revisions bibliogràfiques* 1999;2:8.)
- Prieto L, Alonso J, Lamarca R, Wright BD. Rasch measurement for reducing items of the Nottingham Health Profile. *J Outcome Meas* 1998; 2(4):285-301.
- Prieto L, Lamarca R, Casado A, Alonso J. The evaluation of agreement on continuous variables by the intraclass correlation coefficient. *J Epidemiol Community Health* 1997; 51(5):579-80.

ABSTRACTS PRESENTATIONS**ERS 2021, 5-8 September 2021, virtual event**

Safety of as-needed formoterol in asthma patients on different maintenance long-acting β_2 -agonists. Reddel HK, Brusselle G, Lamarca R, Gustafson P, Anderson GP, Jorup C.

TSANZSRS Annual Scientific Meeting 2020, 27-31 March 2020 (postponed to 2021)

As-needed budesonide/formoterol for adolescents was superior to as-needed terbutaline and comparable to budesonide maintenance for severe exacerbation risk reduction: pooled subgroup analysis of the SYGMA 1 and 2 trials. Reddel HK, Bateman ED, FitzGerald JM, Barnes PJ, Zhong N, Ivanov S, Lamarca R, Puu M, Alagappan V, O'Byrne PM.

Number needed to treat with as-needed budesonide-formoterol or budesonide maintenance to have an additional patient free from a severe or moderate/severe exacerbation: post-hoc analysis of SYGMA 1 in mild asthma. Reddel H, O'Byrne PM, Bateman ED, Barnes PJ, Zheng J, Lamarca R, Puu M, Alagappan V, FitzGerald JM.

ERS 2020, 7-9 September 2020, virtual event

Efficacy of as-needed budesonide/formoterol in mild asthma: pooled analysis of SYGMA 1 and 2. Bateman ED, FitzGerald JM, Reddel HK, Barnes PJ, Zheng J, Lamarca R, Puu M, Ivanov S, Parikh H, Alagappan V, O'Byrne PM. Eur Respir J 56 (suppl 64) 2275; DOI: 10.1183/13993003.congress-2020.2275 Published 28 October 2020

ERS 2019, 28th September to 2nd October 2019, Madrid, Spain

Exacerbation risk after night-time waking due to asthma in SYGMA 1. Reddel HK, Bateman ED, FitzGerald JM, Barnes PJ, Zhong N, Rosa Lamarca R, Puu M, Alagappan V, Whelan G, O'Byrne PM. Eur Respir J 2019 54: PA3715; DOI: 10.1183/13993003.congress-2019.PA3715

Impact of COPD symptom-related attacks on quality of life and exacerbations. Ferguson GT, Gilbert I, Lamarca R, Aksomaityte A, Lythgoe D, Skärby T, Nordenmark L, Trudo F. Eur Respir J 54 (suppl 63) OA258; DOI: 10.1183/13993003.congress-2019.OA258 Published 21 November 2019

Number needed to treat (NNT) to have an additional patient free from a severe or moderate/severe exacerbation: post-hoc analysis of SYGMA 1 in mild asthma. FitzGerald M, O'Byrne PM, Bateman ED, Barnes PJ, Zhong N, Alagappan V, Whelan G, Lamarca R, Puu M, Reddel HK. Eur Respir J 54 (suppl 63) PA3716; DOI: 10.1183/13993003.congress-2019.PA3716 Published 21 November 2019

ATS 2019, 17-22 May 2019 - Dallas, TX

Reduction in COPD Symptom-Related Attacks with Budesonide/Formoterol Versus Formoterol: A Post-Hoc Analysis of the RISE Study. Ferguson GT, Skarby T, Nordenmark LH, Aksomaityte A, Lythgoe D, Lamarca R, Gilbert IA, Trudo F. Am J Respir Crit Care Med 2019;199:A7099

Efficacy of As-Needed Budesonide/Formoterol for Reducing Severe Exacerbations in Adolescents with Mild Asthma: Pooled Subgroup Analysis of the SYGMA 1 and 2 Trials. O'Byrne P, Bateman ED, FitzGerald JM, Barnes PJ, Zhong N, Alagappan VKT, Ivanov S, Whelan G, Lamarca R, Puu M, Reddel HK. Am J Respir Crit Care Med 2019;199:A7191

Influence of Prior Treatment Upon the Efficacy of As-Needed Budesonide/Formoterol in Mild Asthma in the SYGMA 1 and 2 Studies. Bateman E, O'Byrne PM, FitzGerald JM, Barnes PJ, Zhong N, Alagappan V, Whelan G, Lamarca R, Puu M, Reddel HK. Am J Respir Crit Care Med 2019;199:A7082

ERS 2018, 15-19 September 2018, Paris, France

Risk of a severe exacerbation following higher reliever use: post-hoc analysis of SYGMA 1 in mild asthma. O'Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, Wang M, Lamarca R, Puu M, Reddel HK. Eur Respir J 2018 52: OA1680; DOI:10.1183/13993003.congress-2018.OA1680

ATS 2018, 18-23 May 2018 - San Diego, CA

Severe Exacerbations and Inhaled Corticosteroid Load with As-Needed Budesonide/Formoterol vs Maintenance Budesonide in Mild Asthma. Bateman ED, Reddel HK, O'Byrne PM, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Siwek-Posluszna A, FitzGerald M. Am J Respir Crit Care Med 2018;197:A7654

Efficacy and Safety of As-needed Budesonide/Formoterol in Mild Asthma. O'Byrne P, FitzGerald M, Bateman ED, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Ivanov S, Reddel HK. *Am J Respir Crit Care Med* 2018;197:A7655

ACAAI Annual Scientific Meeting 2016

Safety of Budesonide/Formoterol Pressurized Metered-Dose Inhaler Versus Budesonide in Children (6–<12 years) With Asthma. Lanz MJ, Eckerwall G, McLaren J, Lamarca R, Puu M, Jorup C, Sandin K, Pearlman DS

Efficacy of Budesonide/Formoterol Pressurized Metered-Dose Inhaler versus Budesonide Alone in Children (6–<12 years) With Asthma. Pearlman DS, Eckerwall G, McLaren J, Lamarca R, Puu M, Jorup C, Sandin K, Lanz MJ

EADV 2016, 28 September - 2 October 2016, Vienna, Austria

Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: Results of the BRIDGE study. P Van de Kerkhof, JC Szepletowski, R Loewe, R Lamarca, W-G Ocker, VM Tebbs, I Pau-Charles, U Mrowietz.

Treatment with LAS41008 (dimethyl fumarate) improves health-related quality of life and has a positive impact on the patient benefit index in adults with moderate-to-severe chronic plaque psoriasis: Results of the BRIDGE study. P Van de Kerkhof, JC Szepletowski, R Loewe, R Lamarca, W-G Ocker, VM Tebbs, I Pau-Charles, U Mrowietz.

SEPAR 2016, 10-13 June 2016, Granada, Spain

Síntomas matutinos y nocturnos en EPOC y eficacia de aclidinio/formoterol en pacientes sintomáticos vs. asintomáticos. M Miravittles, E Garcia Gil, F Chuecos, R Lamarca

ERS 2015, 26-30 September 2015, Amsterdam, the Netherlands

Morning and nighttime symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. Miravittles M, Garcia-Gil E, Chuecos F, Lamarca R. *Eur Respir J* 2015; 46 (suppl 59) OA1968; DOI: 10.1183/13993003.congress-2015.

ATS 2015, 15-20 May 2015, Denver, USA

Performance of the E-RS (EXAcacerbations of Chronic pulmonary disease Tool-Respiratory Symptoms) diary in clinical trials: pooled analysis of two Phase III studies. NK Leidy, PW Jones, A Hareendran, R Lamarca, F Chuecos, E Garcia Gil. *Am J Respir Crit Care Med* 2015; 191:A2546

Aclidinium bromide improves COPD symptoms assessed using the E-RS (EXAcacerbations of Chronic pulmonary disease Tool-Respiratory Symptoms) questionnaire: pooled analysis of two Phase III studies. P W Jones, NK Leidy, A Hareendran, R Lamarca, F Chuecos, E Garcia Gil. *Am J Respir Crit Care Med* 2015;191:A3971

ISPOR 2014, 8-12 November 2014, Amsterdam, The Netherlands

A Comparison of the Reliability and Validity of the Four-Item and Six-Item NiSCI Symptom Summary Scores. M MocarSKI, D Trundell, E Zaiser, E Garcia Gil, R Lamarca, A Hareendran. *Value in Health* 2014;17(7):A601.

ERS 2014, 6-10 September 2014, Munich, Germany

Analysis of comorbidities and treatment patterns by GOLD 2013 criteria: pooled data from Phase III aclidinium bromide studies. D Price, M Thomas, R Lamarca, E Garcia Gil. *Eur Respir J* 2014; 44: (Suppl 58): A892.

Effect of aclidinium bromide on dyspnoea and health status in patients with stable COPD: Phase III data by GOLD 2013 classification. RM Mróz, MP Ausin, R Lamarca, E Garcia Gil. *Eur Respir J* 2014; 44: (Suppl 58): A891.

Inter-relationship of different types of respiratory symptoms in COPD. PW Jones, M Miravittles, F Chuecos, E Garcia Gil, R Lamarca. *Eur Respir J* 2014; 44: (Suppl 58): A3598.

ATS 2013, 17-22 May 2013, Philadelphia, USA

Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. PW. Jones, F Chuecos, R Lamarca, D Singh, A Agusti, ED. Bateman, G de Miquel, C Caracta, E Garcia Gil. *Am J Respir Crit Care Med* 2013;187:A6072.

Efficacy of twice-daily aclidinium bromide 400 µg in subgroups of patients with COPD. E.M. Kerwin, P.W. Jones, A.D. D'Urzo, E. Bateman, R. Lamarca, E. Garcia Gil, C. Caracta. *Am J Respir Crit Care Med* 2013;187:A4265.

BTS, 5-7 December 2012, London, UK

Reduced COPD exacerbations associated with acclidinium bromide versus placebo: a pooled analysis of Phase III data. PW Jones, D Singh, E Kerwin, R Lamarca, C Caracta, E Garcia Gil. Thorax 2012; 67(Suppl 2): A146

ERS 2012, 1-5 September 2012, Vienna, Austria

Acclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: Results from ATTAIn. Jones PW, Singh D, Agusti A, Bateman ED, Lamarca R, de Miquel G, Caracta C, Garcia-Gil E. Eur Respir J 40 (Suppl 56) 195

Pooled analysis of twice-daily acclidinium bromide in COPD patients: Dyspnea and health status in the ACCORD-COPD I and ATTAIn trials. Jones PW, Kerwin E, Bateman ED, Lamarca R, Caracta C, Garcia-Gil E. Eur Respir J 40 (Suppl 56) P2891

AANP 2012, 20-24 June, Orlando, US

Efficacy and Safety of Twice-Daily Acclidinium Bromide in Chronic Obstructive Pulmonary Disease: ACCORD-COPD I and ATTAIn. E Kerwin, A D'Urzo, R Lamarca, L Reveda, R Segarra, C Caracta

WIPO, 21-24 April 2012, New York, US

Efficacy and quality of life of twice-daily acclidinium bromide in chronic obstructive pulmonary disease: The ACCORD-COPD I and ATTAIn studies. P Jones, E Kerwin, E Bateman, R Lamarca, C Caracta, E Garcia Gil

BTS, 7-9 December 2011, London, UK

ATTAIn: twice-daily acclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease. Singh D, Jones PJ, Bateman ED, Agusti A, Lamarca R, de Miquel G, Caracta C, Garcia Gil E. Thorax 2011; 66 (Suppl 4); A117 (Abstract P255)

CHEST 2011 18-22 October, Honolulu, Hawaii

ATTAIn: efficacy and safety of twice-daily acclidinium bromide in chronic obstructive pulmonary disease (COPD). P Jones, E Bateman, D Singh, A Agusti, R Lamarca, G de Miquel, C Caracta, E Garcia Gil. Chest October 2011 140:4 Meeting Abstracts 975A; doi:10.1378/chest.1111549

Acclidinium bromide in patients with chronic obstructive pulmonary disease: improvement in symptoms and health status in the ATTAIn study. P Jones, A Agusti, E Bateman, D Singh, R Lamarca, G de Miquel, C Caracta, E Garcia Gil. Chest October 2011 140:4 Meeting Abstracts 547A; doi:10.1378/chest.1119097

Acclidinium bromide in patients with COPD: reduction in exacerbations as defined by health-care utilization and the EXACT diary card. P Jones, D Singh, A Agusti, E Bateman, R Lamarca, G de Miquel, C Caracta, E Garcia Gil. Chest October 2011 140:4 Meeting Abstracts 529A; doi:10.1378/chest.1111458

ERS 2011, 24-28 September, Amsterdam, The Netherlands

The ATTAIn study: bronchodilatory effect of acclidinium bromide in chronic obstructive pulmonary disease (COPD). D Singh, ED Bateman, PW Jones, A Agusti, R Lamarca, G de Miquel, C Caracta, E Garcia Gil. Eur Respir J 2011; 38 (Suppl 55): 149s.

The ATTAIn study: safety and tolerability of acclidinium bromide in chronic obstructive pulmonary disease. ED Bateman, D Singh, PW Jones, A Agusti, R Lamarca, G de Miquel, C Caracta, E Garcia Gil. Eur Respir J 2011; 38 (Suppl 55): 730s

Acclidinium bromide in patients with chronic obstructive pulmonary disease: improvement in health status in ATTAIn. PW Jones, A Agusti, ED Bateman, D Singh, R Lamarca, F de Miquel, C Caracta, E Garcia Gil. Eur Respir J 2011; 38 (Suppl 55): 150s

Improvement in symptoms and rescue medication use with acclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIn. A Agusti, PW Jones, ED Bateman, D Singh, R Lamarca, C Caracta, E Garcia Gil. Eur Respir J 2011; 38 (Suppl 55): 149s

ATS, 13-18 May 2011, Denver, US

Acclidinium Bromide In Patients With Chronic Obstructive Pulmonary Disease: Efficacy And Safety Results From ATTAIn. PW Jones, A Agusti, ED Bateman, D Singh, R Lamarca, G de Miquel, C. Caracta, E Garcia Gil. Am J Respir Crit Care Med 2011; 183: A6350

CHEST 28-30 October 2008, Philadelphia, USA

Acclidinium bromide shows good pulmonary deposition. R Greguletz, S Newman, D Sutton, R Segarra, R Lamarca, G de Miquel. *Chest* 2008 134 (Issue 4): p107002S

ERS 4-8 October 2008, Berlin, Germany

Once-daily administration of acclidinium bromide, a novel, long-acting anticholinergic: a Phase II, dose-finding study. P Chanez, S Burge, R Dahl, J Creemers, R Lamarca, E Garcia Gil. *Eur Respir J* 2008; 32 (Suppl 52): 476s

Low systemic exposure to acclidinium bromide, a novel long-acting anticholinergic, after multiple doses. G de Miquel, A Schrödter, B Miletzki, M Gurniak, R Lamarca, JM Jansat. *Eur Respir J* 2008; 32 (Suppl 52): 630s

In vivo pulmonary deposition of acclidinium bromide from a multidose dry powder inhaler. S Newman, D Sutton, R Segarra, R Lamarca, G de Miquel. *Eur Respir J* 2008; 32 (Suppl 52): 476s

ATS 16-21 May 2008, Toronto, Canada

Once-daily administration of acclidinium bromide, a novel, long-acting anticholinergic: a Phase II, dose-finding study. P Chanez, S Burge, R Dahl, J Creemers, R Lamarca, E Garcia Gil. *Am J Respir Crit Care Med* 2008; 177 (Abstracts Issue): A650

Chanez P, Burge S, Dahl R, Creemers J, Lamarca R, Garcia Gil E. Once-daily administration of acclidinium bromide, a novel, long-acting anticholinergic: a Phase II, dose-finding study. *Am J Respir Crit Care Med* 2008; 177 (Abstracts Issue): A650.

Miscellanea

Pizarro V, Ferrer M, Orfila F, Lamarca R, Alonso J. Estado de salud dental de personas mayores no institucionalizadas de Barcelona. *Gaceta Sanitaria* 2003;17 (Sup 2):74-76.

Murio C, Miravittles M, Lamarca R et al. Factores de riesgo para las agudizaciones de EPOC. *Arch Bronconeumol* 2001; 37(Supl 1): 102.

Miravittles M, Vidal R, Lamarca R et al. Influence of antibiotic treatment on duration of symptoms of acute exacerbations of COPD. *Am J Respir Crit Care Med* 2001; 165: A269.

Aymerich M, Ferrer M, Haro JM, Palacín C, Márquez M, Rodríguez MJ, Usall J, Autonell J, Lamarca R, Alonso J. Adaptación al español del CIDI 2000 para la iniciativa de la OMS 'World Mental Health 2000 (WMH-2000)' 2000;

Lamarca R, Ferrer M, Andersen PK, Liestol K, Keiding N, Alonso J. Is the relationship between disability and mortality the same at different ages? *The Gerontologist* 1999;39(1):26.

Lamarca R, Ferrer M, Alonso J. Cross-sectional and longitudinal relationship between the Nottingham Health Profile and functional capacity in the elderly. *Qual Life Res* 1999;8(7):653.

Miravittles M, Vidal R, Lamarca R, Álvarez-Sala JL, Masa JF, Vereá H, Zalacain R, Ros F. Health-related quality of life of moderate-to-sever ambulatory COPD patients. *Qual Life Res* 1999;8(7):662.

Prieto L, Lamarca R, Santed R, Alonso J. Classical test theory versus Rasch analysis for health-related quality of life questionnaire reduction. *Qual Life Res* 1999;8(7):652.

Miravittles M, Vidal R, Lamarca R, Álvarez-Sala JL, Masa JF, Vereá H, Zalacain R, Ros F on behalf of the IMPAC study group. Health-related quality of life of moderate-to-sever ambulatory COPD patients. *Eur Respir J* 1999;14(Supl 30):414s.

Alonso J, Lamarca R, Prieto L, Santed R. Comparación de la versión española del Perfil de Salud de Nottingham en diferentes grupos de la población española. *Rev Esp Salud Pública* 1998; 72 Supl:75-6.

Alonso J, Lamarca R, for the International Cataract Surgery Outcome Study. Disagreement between clinical measures and perceived health reports: lessons to be learned from a study of cataracts surgery. *Qual Life News Lett* 1998; (Spec Issue March): 7.

Prieto L, Lamarca R, Alonso J, Wright BD. El análisis Rasch para la reducción de cuestionarios: aplicación al Perfil de Salud de Nottingham. *Rev Esp Salud Pública* 1998; 72 Supl:74-5.

Alonso J, Prieto L, Valderas JM, Espallargues M, Lamarca R. Interpretación de las medidas de salud percibida: ejemplo del Índice VF-14 en pacientes con cataratas. *Rev Esp Salud Pública* 1998; 72 Supl:135.

Prieto L, Lamarca R, Santed R, McFarlane D, Sanzo JM, Alonso J. Reducing the items of the Nottingham Health Profile. *Qual Life Res* 1997;6(7/8).

Prieto L, Lamarca R, Santed R, McFarlane D, Sanzo JM, Viladrich MC, Saez M, Alonso J. The Nottingham Health Profile: metric properties in different Spanish settings and need of a short form for the clinical practice. *J Economie Medicale* 1996; 14 (supl): 54.

Ferrer M, Orfila F, Lamarca R, Alonso J. Comparación de la capacidad funcional declarada con la objetivada en los ancianos. *Gac Sanit* 1996; 10, 56 (supl 2): 81.

Lamarca R, Gómez G, Ferrer M, Orfila F, Alonso J. Edad como escala de tiempo: un método alternativo para el análisis de supervivencia en los estudios de ancianos. *Gac Sanit* 1996; 10, 56 (supl 2): 82.

Orfila F, Ferrer M, Lamarca R, Alonso J. Evolución de la salud de los ancianos. Resultados de un estudio longitudinal en la ciudad de Barcelona. *Gac Sanit* 1996; 10, 56 (supl 2): 105

KEY TRAINING in LEADERSHIP

Leading Business. Duke Corporate Education. 12-week programme May-July 2021

Influencing Masterclass. Red10, 18th-19th November 2020.

Coaching program. Red10 2018

Inspiring leaders 2 R&D. P. Marques. 27th-28th October 2015.

Inspiring leaders 1 R&D. L. 8th-9th July 2015.

Smart leaders programme.

OTHERS

Member of the experts committee in *Medicina Clinica* (Bcn) jornal, 2002-2010

Adhoc reviewer for the *European Respiratory Journal*.

PRIZES and GRANTS

Symbicort team being recognised as a highly commended finalist in the 2018 GMD Awards

Almirall Innovation award in 2015.

Prize 'Agrupación Mutua' to the research in elderly population.

Prize to the best article in the gerontology field in 1999.

Prize of the XIV Scientific meeting of the Spanish Society of Epidemiology, prize for the 10 best presentations. August, 1996- Zaragoza.

Prize of the 5th Annual Conference of the Spanish biometry: prize to best oral presentation by a student. June 1995- Valencia.

Grant from Instituto de Salud Carlos III de Madrid (FIS, Expte.: 97/4364).

Grant for training researchers 1997-99 Madrid.

Grant of the 16th Meeting of the International Society for Clinical Biostatistics, August 1995- Barcelona.

Grant of the 5ª Conferencia Española de Biometría to attend to the meeting, June 1995- Valencia.

Grant of the VIII Universitat Tècnica d'Estiu de Catalunya (UTECE), July 1994 - Sitges.